Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Plasma Fractionation Market, by Product
1.4.2 North America Plasma Fractionation Market, by Sector
1.4.3 North America Plasma Fractionation Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Plasma Fractionation Market by Product
3.1 North America Immunoglobulins Market by Country
3.2 North America Albumin Market by Country
3.3 North America Coagulation factor VIII Market by Country
3.4 North America Coagulation factor IX Market by Country
Chapter 4. North America Plasma Fractionation Market by Sector
4.1 North America Private Sector Market by Country
4.2 North America Public Sector Market by Country
Chapter 5. North America Plasma Fractionation Market by Country
5.1 US Plasma Fractionation Market
5.1.1 US Plasma Fractionation Market by Product
5.1.2 US Plasma Fractionation Market by Sector
5.2 Canada Plasma Fractionation Market
5.2.1 Canada Plasma Fractionation Market by Product
5.2.2 Canada Plasma Fractionation Market by Sector
5.3 Mexico Plasma Fractionation Market
5.3.1 Mexico Plasma Fractionation Market by Product
5.3.2 Mexico Plasma Fractionation Market by Sector
5.4 Rest of North America Plasma Fractionation Market
5.4.1 Rest of North America Plasma Fractionation Market by Product
5.4.2 Rest of North America Plasma Fractionation Market by Sector
Chapter 6. Company Profiles
6.1 Emergent BioSolutions, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Regional Analysis
6.1.4 Research & Development Expense
6.2 CSL Limited
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.2.5 Recent strategies and developments:
6.2.5.1 Acquisition and Mergers:
6.3 Grifols S.A.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.1 Recent strategies and developments:
6.3.1.1 Acquisition and Mergers:
6.4 Octapharma AG
6.4.1 Company Overview
6.4.2 Recent strategies and developments:
6.4.2.1 Approvals:
6.4.2.2 Partnerships, Collaborations, and Agreements:
6.5 Takeda Pharmaceutical Company Limited
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Regional Analysis
6.5.4 Research & Development Expense
6.6 Kedrion S.p.A
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Regional Analysis
6.6.4 Research & Development Expense
6.6.5 Recent strategies and developments:
6.6.5.1 Partnerships, Collaborations, and Agreements:
6.7 LFB S.A.
6.7.1 Company Overview
6.8 Biotest AG (Tiancheng International Investment Limited)
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental and Regional Analysis
6.8.4 Research & Development Expense
6.9 Sanquin Blood Supply Foundation
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expense
6.10. Bio Products Laboratory Limited
6.10.1 Company Overview
6.10.2 Recent strategies and developments:
6.10.2.1 Product Launches and Product Expansions:
Unique Offerings 